Keros Therapeutics, Inc. - Common Stock (KROS)
CUSIP: 492327101
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 19,711,307
- Total 13F shares
- 31,483,081
- Share change
- +105,512
- Total reported value
- $1,437,735,495
- Put/Call ratio
- 6.3%
- Price per share
- $45.70
- Number of holders
- 150
- Value change
- -$1,704,535
- Number of buys
- 84
- Number of sells
- 57
Quarterly Holders Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 492327101:
Top shareholders of KROS - Keros Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
25%
|
5,018,516
|
$332,225,759 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
11%
|
2,166,010
|
$143,389,863 | — | 31 Mar 2024 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
8.1%
|
1,598,907
|
$105,847,644 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
7.9%
|
1,562,895
|
$103,463,649 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.8%
|
1,545,758
|
$102,329,179 | — | 31 Mar 2024 | |
| Darwin Global Management, Ltd. |
13F
|
Company |
7.3%
|
1,435,950
|
$95,059,890 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
6.4%
|
1,268,734
|
$83,990,191 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
6.2%
|
1,218,504
|
$80,666,000 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
4.9%
|
971,881
|
$64,338,522 | — | 31 Mar 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
4.5%
|
879,344
|
$58,212,573 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
3.9%
|
761,700
|
$50,424,540 | — | 31 Mar 2024 | |
| BRAIDWELL LP |
13F
|
Company |
3.7%
|
737,379
|
$48,814,490 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
3.4%
|
680,000
|
$45,016,000 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
3.3%
|
651,999
|
$43,162,334 | — | 31 Mar 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
3.2%
|
637,983
|
$42,234,475 | — | 31 Mar 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
3.2%
|
633,671
|
$41,949,020 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
3.2%
|
632,049
|
$41,841,644 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3%
|
595,846
|
$39,450,450 | — | 31 Mar 2024 | |
| Redmile Group, LLC |
13F
|
Company |
2.8%
|
552,506
|
$36,575,897 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.3%
|
450,278
|
$29,808,404 | — | 31 Mar 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
1.9%
|
367,500
|
$24,328,500 | — | 31 Mar 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.7%
|
338,243
|
$22,391,687 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.7%
|
337,663
|
$22,353,291 | — | 31 Mar 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.5%
|
293,997
|
$19,462,601 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.5%
|
289,157
|
$19,142,193 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.4%
|
273,600
|
$18,112,320 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
272,971
|
$18,070,680 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
258,368
|
$17,103,961 | — | 31 Mar 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.2%
|
238,806
|
$15,808,985 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.2%
|
235,638
|
$15,599,235 | — | 31 Mar 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
1.1%
|
209,700
|
$13,882,140 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.1%
|
207,758
|
$13,753,580 | — | 31 Mar 2024 | |
| CIBC WORLD MARKETS CORP |
13F
|
Company |
1%
|
200,000
|
$13,240,000 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.96%
|
190,000
|
$12,578,000 | — | 31 Mar 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
0.95%
|
187,500
|
$12,412,500 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.9%
|
178,335
|
$11,805,777 | — | 31 Mar 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.88%
|
172,633
|
$11,428,305 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.88%
|
172,477
|
$11,417,978 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.84%
|
165,406
|
$10,949,876 | — | 31 Mar 2024 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.76%
|
149,013
|
$9,864,661 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.63%
|
124,185
|
$8,221,047 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.63%
|
124,072
|
$8,213,566 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.61%
|
119,511
|
$7,911,628 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.6%
|
117,456
|
$7,775,586 | — | 31 Mar 2024 | |
| WCM INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.59%
|
117,030
|
$7,747,386 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.51%
|
101,239
|
$6,702,022 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.51%
|
99,633
|
$6,595,704 | — | 31 Mar 2024 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
0.48%
|
94,373
|
$6,247,493 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.47%
|
91,858
|
$6,081,000 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.45%
|
88,683
|
$5,870,815 | — | 31 Mar 2024 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock (KROS) as of Q2 2024
As of 30 Jun 2024,
Keros Therapeutics, Inc. - Common Stock (KROS) was held by
150 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,483,081 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., VANGUARD GROUP INC, ALKEON CAPITAL MANAGEMENT LLC, Darwin Global Management, Ltd., ORBIMED ADVISORS LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, BRAIDWELL LP, and Jefferies Financial Group Inc..
This page lists
150
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
144
Q2 2024 holders
150
Holder diff
6
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.